Latest news with #AmphastarPharmaceuticals
Yahoo
27-05-2025
- Business
- Yahoo
Evolent Health, Amphastar Pharmaceuticals, Iridium, and Magnite Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +2.0%) as President Trump postponed the planned 50% tariff on European Union imports, shifting the start date to July 9, 2025. Companies with substantial business ties to Europe likely had some relief as the delay reduced near-term cost pressures and preserved cross-border demand. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Healthcare Technology for Providers company Evolent Health (NYSE:EVH) jumped 5.6%. Is now the time to buy Evolent Health? Access our full analysis report here, it's free. Generic Pharmaceuticals company Amphastar Pharmaceuticals (NASDAQ:AMPH) jumped 5%. Is now the time to buy Amphastar Pharmaceuticals? Access our full analysis report here, it's free. Satellite Telecommunication Services company Iridium (NASDAQ:IRDM) jumped 5.7%. Is now the time to buy Iridium? Access our full analysis report here, it's free. Advertising & Marketing Services company Magnite (NASDAQ:MGNI) jumped 5.6%. Is now the time to buy Magnite? Access our full analysis report here, it's free. Iridium's shares are quite volatile and have had 17 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Iridium is down 11.2% since the beginning of the year, and at $26.27 per share, it is trading 21.7% below its 52-week high of $33.57 from October 2024. Investors who bought $1,000 worth of Iridium's shares 5 years ago would now be looking at an investment worth $1,099. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio
Yahoo
08-05-2025
- Business
- Yahoo
Earnings To Watch: ANI Pharmaceuticals (ANIP) Reports Q1 Results Tomorrow
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be announcing earnings results tomorrow before market hours. Here's what to expect. ANI Pharmaceuticals beat analysts' revenue expectations by 8.5% last quarter, reporting revenues of $190.6 million, up 44.8% year on year. It was a stunning quarter for the company, with a solid beat of analysts' full-year EPS guidance estimates and full-year revenue guidance exceeding analysts' expectations. Is ANI Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting ANI Pharmaceuticals's revenue to grow 30.7% year on year to $179.6 million, improving from the 28.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.38 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. ANI Pharmaceuticals has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 5.7% on average. Looking at ANI Pharmaceuticals's peers in the generic pharmaceuticals segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Amneal delivered year-on-year revenue growth of 5.5%, missing analysts' expectations by 3.4%, and Amphastar Pharmaceuticals reported flat revenue, falling short of estimates by 2%. Amneal traded down 2.4% following the results. Read our full analysis of Amneal's results here and Amphastar Pharmaceuticals's results here. Investors in the generic pharmaceuticals segment have had steady hands going into earnings, with share prices flat over the last month. ANI Pharmaceuticals is up 8.8% during the same time and is heading into earnings with an average analyst price target of $81.88 (compared to the current share price of $71.82). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
30-04-2025
- Business
- Associated Press
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market closes on Wednesday, May 7th, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference. The call can also be accessed on the Investors page on the Company's website The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call. Company Information Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at Forward Looking Statements All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits BAQSIMI®, including its potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'anticipate,' 'predict,' 'potential,' 'continue,' 'expect,' 'intend,' 'plan,' 'project,' 'believe,' 'estimate,' and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025 and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at and on the SEC's website at The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change. Contact: Bill Peters Chief Financial Officer (909) 476-3416 SOURCE: Amphastar Pharmaceuticals, Inc. press release
Yahoo
30-04-2025
- Business
- Yahoo
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025
RANCHO CUCAMONGA, CA / / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market closes on Wednesday, May 7th, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference. The call can also be accessed on the Investors page on the Company's website The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call. Company Information Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at Forward Looking Statements All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits BAQSIMI®, including its potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025 and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at and on the SEC's website at The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change. Contact: Bill PetersChief Financial Officer(909) 476-3416 SOURCE: Amphastar Pharmaceuticals, Inc. View the original press release on ACCESS Newswire
Yahoo
24-04-2025
- Automotive
- Yahoo
2 Safe-and-Steady Stocks with Solid Fundamentals and 1 to Think Twice About
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Finding the right balance between safety and returns isn't easy, which is why StockStory is here to help. That said, here are two low-volatility stocks that could succeed under all market conditions and one stuck in limbo. Rolling One-Year Beta: 0.02 With Corn Flakes as its first and most iconic product, Kellanova (NYSE:K) is a packaged foods company that is dominant in the cereal and snack categories. Why Are We Hesitant About K? Falling unit sales over the past two years indicate demand is soft and that the company may need to revise its product strategy Sales are projected to be flat over the next 12 months and imply weak demand Earnings per share have dipped by 2.5% annually over the past three years, which is concerning because stock prices follow EPS over the long term At $82.69 per share, Kellanova trades at 21.1x forward price-to-earnings. Dive into our free research report to see why there are better opportunities than K. Rolling One-Year Beta: 0.26 Aiming to be a one-stop shop for the DIY customer, AutoZone (NYSE:AZO) is an auto parts and accessories retailer that sells everything from car batteries to windshield wiper fluid to brake pads. Why Does AZO Catch Our Eye? Same-store sales growth lends it the confidence to gradually expand its store base so it can reach more customers Differentiated product assortment is reflected in its best-in-class gross margin of 53% Strong free cash flow margin of 11.1% enables it to reinvest or return capital consistently AutoZone is trading at $3,655 per share, or 22.5x forward price-to-earnings. Is now the right time to buy? Find out in our full research report, it's free. Rolling One-Year Beta: 0.69 Founded in 1996 and known for its expertise in complex drug formulations, Amphastar Pharmaceuticals (NASDAQ:AMPH) develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products. Why Does AMPH Stand Out? Market share has increased this cycle as its 21.1% annual revenue growth over the last two years was exceptional Free cash flow margin jumped by 16.9 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends Improving returns on capital reflect management's ability to monetize investments Amphastar Pharmaceuticals's stock price of $23.33 implies a valuation ratio of 6.3x forward price-to-earnings. Is now the time to initiate a position? See for yourself in our in-depth research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Sterling Infrastructure (+1,096% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
